Genome-wide analysis of alternative transcripts in human breast cancer

Ji Wen, Kevin H. Toomer, Zhibin Chen, Xiaodong Cai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Transcript variants play a critical role in diversifying gene expression. Alternative splicing is a major mechanism for generating transcript variants. A number of genes have been implicated in breast cancer pathogenesis with their aberrant expression of alternative transcripts. In this study, we performed genome-wide analyses of transcript variant expression in breast cancer. With RNA-Seq data from 105 patients, we characterized the transcriptome of breast tumors, by pairwise comparison of gene expression in the breast tumor versus matched healthy tissue from each patient. We identified 2839 genes, ~10 % of protein-coding genes in the human genome, that had differential expression of transcript variants between tumors and healthy tissues. The validity of the computational analysis was confirmed by quantitative RT-PCR assessment of transcript variant expression from four top candidate genes. The alternative transcript profiling led to classification of breast cancer into two subgroups and yielded a novel molecular signature that could be prognostic of patients’ tumor burden and survival. We uncovered nine splicing factors (FOX2, MBNL1, QKI, PTBP1, ELAVL1, HNRNPC, KHDRBS1, SFRS2, and TIAR) that were involved in aberrant splicing in breast cancer. Network analyses for the coordinative patterns of transcript variant expression identified twelve “hub” genes that differentiated the cancerous and normal transcriptomes. Dysregulated expression of alternative transcripts may reveal novel biomarkers for tumor development. It may also suggest new therapeutic targets, such as the “hub” genes identified through the network analyses of transcript variant expression, or splicing factors implicated in the formation of the tumor transcriptome.

Original languageEnglish (US)
Pages (from-to)295-307
Number of pages13
JournalBreast Cancer Research and Treatment
Volume151
Issue number2
DOIs
StatePublished - Apr 26 2015

Fingerprint

Genome
Breast Neoplasms
Transcriptome
Genes
Gene Expression Profiling
Gene Expression
Alternative Splicing
Human Genome
Tumor Biomarkers
Tumor Burden
Neoplasms
RNA
Polymerase Chain Reaction
Survival
Proteins
RNA Splicing Factors
Therapeutics

Keywords

  • Alternative transcript
  • Breast cancer
  • Classification
  • Network
  • Splicing
  • Transcriptome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Genome-wide analysis of alternative transcripts in human breast cancer. / Wen, Ji; Toomer, Kevin H.; Chen, Zhibin; Cai, Xiaodong.

In: Breast Cancer Research and Treatment, Vol. 151, No. 2, 26.04.2015, p. 295-307.

Research output: Contribution to journalArticle

@article{55f7bc298f0f40a8a3aef593030b64d6,
title = "Genome-wide analysis of alternative transcripts in human breast cancer",
abstract = "Transcript variants play a critical role in diversifying gene expression. Alternative splicing is a major mechanism for generating transcript variants. A number of genes have been implicated in breast cancer pathogenesis with their aberrant expression of alternative transcripts. In this study, we performed genome-wide analyses of transcript variant expression in breast cancer. With RNA-Seq data from 105 patients, we characterized the transcriptome of breast tumors, by pairwise comparison of gene expression in the breast tumor versus matched healthy tissue from each patient. We identified 2839 genes, ~10 {\%} of protein-coding genes in the human genome, that had differential expression of transcript variants between tumors and healthy tissues. The validity of the computational analysis was confirmed by quantitative RT-PCR assessment of transcript variant expression from four top candidate genes. The alternative transcript profiling led to classification of breast cancer into two subgroups and yielded a novel molecular signature that could be prognostic of patients’ tumor burden and survival. We uncovered nine splicing factors (FOX2, MBNL1, QKI, PTBP1, ELAVL1, HNRNPC, KHDRBS1, SFRS2, and TIAR) that were involved in aberrant splicing in breast cancer. Network analyses for the coordinative patterns of transcript variant expression identified twelve “hub” genes that differentiated the cancerous and normal transcriptomes. Dysregulated expression of alternative transcripts may reveal novel biomarkers for tumor development. It may also suggest new therapeutic targets, such as the “hub” genes identified through the network analyses of transcript variant expression, or splicing factors implicated in the formation of the tumor transcriptome.",
keywords = "Alternative transcript, Breast cancer, Classification, Network, Splicing, Transcriptome",
author = "Ji Wen and Toomer, {Kevin H.} and Zhibin Chen and Xiaodong Cai",
year = "2015",
month = "4",
day = "26",
doi = "10.1007/s10549-015-3395-2",
language = "English (US)",
volume = "151",
pages = "295--307",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Genome-wide analysis of alternative transcripts in human breast cancer

AU - Wen, Ji

AU - Toomer, Kevin H.

AU - Chen, Zhibin

AU - Cai, Xiaodong

PY - 2015/4/26

Y1 - 2015/4/26

N2 - Transcript variants play a critical role in diversifying gene expression. Alternative splicing is a major mechanism for generating transcript variants. A number of genes have been implicated in breast cancer pathogenesis with their aberrant expression of alternative transcripts. In this study, we performed genome-wide analyses of transcript variant expression in breast cancer. With RNA-Seq data from 105 patients, we characterized the transcriptome of breast tumors, by pairwise comparison of gene expression in the breast tumor versus matched healthy tissue from each patient. We identified 2839 genes, ~10 % of protein-coding genes in the human genome, that had differential expression of transcript variants between tumors and healthy tissues. The validity of the computational analysis was confirmed by quantitative RT-PCR assessment of transcript variant expression from four top candidate genes. The alternative transcript profiling led to classification of breast cancer into two subgroups and yielded a novel molecular signature that could be prognostic of patients’ tumor burden and survival. We uncovered nine splicing factors (FOX2, MBNL1, QKI, PTBP1, ELAVL1, HNRNPC, KHDRBS1, SFRS2, and TIAR) that were involved in aberrant splicing in breast cancer. Network analyses for the coordinative patterns of transcript variant expression identified twelve “hub” genes that differentiated the cancerous and normal transcriptomes. Dysregulated expression of alternative transcripts may reveal novel biomarkers for tumor development. It may also suggest new therapeutic targets, such as the “hub” genes identified through the network analyses of transcript variant expression, or splicing factors implicated in the formation of the tumor transcriptome.

AB - Transcript variants play a critical role in diversifying gene expression. Alternative splicing is a major mechanism for generating transcript variants. A number of genes have been implicated in breast cancer pathogenesis with their aberrant expression of alternative transcripts. In this study, we performed genome-wide analyses of transcript variant expression in breast cancer. With RNA-Seq data from 105 patients, we characterized the transcriptome of breast tumors, by pairwise comparison of gene expression in the breast tumor versus matched healthy tissue from each patient. We identified 2839 genes, ~10 % of protein-coding genes in the human genome, that had differential expression of transcript variants between tumors and healthy tissues. The validity of the computational analysis was confirmed by quantitative RT-PCR assessment of transcript variant expression from four top candidate genes. The alternative transcript profiling led to classification of breast cancer into two subgroups and yielded a novel molecular signature that could be prognostic of patients’ tumor burden and survival. We uncovered nine splicing factors (FOX2, MBNL1, QKI, PTBP1, ELAVL1, HNRNPC, KHDRBS1, SFRS2, and TIAR) that were involved in aberrant splicing in breast cancer. Network analyses for the coordinative patterns of transcript variant expression identified twelve “hub” genes that differentiated the cancerous and normal transcriptomes. Dysregulated expression of alternative transcripts may reveal novel biomarkers for tumor development. It may also suggest new therapeutic targets, such as the “hub” genes identified through the network analyses of transcript variant expression, or splicing factors implicated in the formation of the tumor transcriptome.

KW - Alternative transcript

KW - Breast cancer

KW - Classification

KW - Network

KW - Splicing

KW - Transcriptome

UR - http://www.scopus.com/inward/record.url?scp=84937761220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937761220&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3395-2

DO - 10.1007/s10549-015-3395-2

M3 - Article

C2 - 25913416

AN - SCOPUS:84937761220

VL - 151

SP - 295

EP - 307

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -